Equity Overview
Price & Market Data
Price: $4.70
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $34,702,544
Volume: 0
Performance Metrics
1 Week: 12.98%
1 Month: -9.09%
3 Months: -25.87%
6 Months: -39.74%
1 Year: -43.10%
YTD: -30.06%
Company Details
Employees: 55
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.